Fry Terry J
Gates Institute; Pediatrics and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Blood Cancer Discov. 2025 May 5;6(3):157-158. doi: 10.1158/2643-3230.BCD-25-0017.
Since the recognition of the allogeneic graft-versus-leukemia effect, acute myeloid leukemia (AML) has been identified as a T cell-targetable malignancy, but success with modern forms of immunotherapy has been slower than anticipated. In this issue, we discuss the biological barriers to the treatment of AML with T-cell therapy revealed by recent reports, including mechanistic insights into AML resistance to T cell-mediated killing by Tin and colleagues. See related article by Tin et al., p. 217.
自从认识到异基因移植物抗白血病效应以来，急性髓系白血病（AML）就被确定为一种可靶向T细胞的恶性肿瘤，但现代免疫疗法的成功进展比预期要慢。在本期中，我们讨论了近期报告所揭示的采用T细胞疗法治疗AML的生物学障碍，包括Tin及其同事对AML抵抗T细胞介导杀伤的机制性见解。见Tin等人的相关文章，第217页。
